Market research
CLSN Celsion Corp
NASDAQ USD Healthcare
Latest close
Loading market data…
Test a moving-average rule with historical data.
- Market cap
- 14M
- P/E ratio
- Not available
- Analyst target
- 27
- Dividend yield
- 0.0%
- Beta
- 2.26
Profile
Company facts
- Exchange
- NASDAQ
- Currency
- USD
- Sector
- Healthcare
- Industry
- Biotechnology & Medical Research
- ISIN
- US15117N6022
- Market cap
- 14M
- P/E ratio
- Not available
- Analyst target
- 27
- Dividend yield
- 0.0%
- Beta
- 2.26
About
About Celsion Corp
Celsion Corporation, a clinical stage biotechnology company, focuses on the development and commercialization of DNA-based immunotherapies, vaccines, and directed chemotherapies. Its product pipeline includes GEN-1, a DNA-based immunotherapy for the localized treatment of ovarian cancer; and ThermoDox, a proprietary heat-activated liposomal encapsulation of doxorubicin, which is in development stage for various cancer indications. The company also has two feasibility stage platform technologies for the development of nucleic acid-based immunotherapies, vaccines, and other anti-cancer DNA or RNA therapies. Celsion Corporation was founded in 1982 and is based in Lawrenceville, New Jersey.
Visit company websiteCommunity
Investor discussion
1 comment
Sign in to join the CLSN discussion.
5 years, 4 months ago
Celsion Corporation is currently in a long term uptrend where the price is trading 1.0% above its 200 day moving average.
From a valuation standpoint, the stock is 93.0% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 93.3.
Celsion Corporation's total revenue sank by 0.0% to $125K since the same quarter in the previous year.
Its net income has increased by 2.9% to $-3M since the same quarter in the previous year.
Finally, its free cash flow grew by 33.6% to $-4M since the same quarter in the previous year.
Based on the above factors, Celsion Corporation gets an overall score of 4/5.